Scoliosis Sos Limited

Scoliosis Sos Limited is a private limited company registered in England/Wales with the registration number 05464465. Founded nineteen years ago on May 26, 2005, it's a small company, active, and employs twenty-seven people. The company operates from a real address at E1 8AN, London, and is led by a single director and owner, Erika Maude. It specializes in the provision of intensive rehabilitation treatment and equipment, operating as a specialist in non-surgical scoliosis treatment.

The company’s website showcases a range of services, including initial consultations, virtual therapy, treatment courses, and the proprietary ScolioGold therapy—a specialized exercise program. It also highlights research results, patient stories, and overseas patient support. The website has a good amount of content and seems to be a primary driver of business, with no obvious e-commerce functionality. The company also owns two other companies, Scoliosis Sos (kingston) Limited, and Scoliosis Sos (bristol) Limited.

Financially, Scoliosis Sos Limited presents a mixed picture. Cash and cash equivalents decreased by 23% to £260,000, while bank borrowings remained relatively stable. However, net assets increased by 3.2% to £5.9 million. Creditors decreased by 38%, suggesting improved debt management. Trade debtors, however, jumped a significant 650% to £69,000, which could indicate delayed payments or an expansion of credit terms. The company’s assets are substantial, with investment property valued at £1.6 million. Despite the growth in net assets, the increase in trade debtors warrants attention. The company is exempt from an audit due to its small size, meaning the financial statements are unaudited. Overall, the company appears to be financially stable, but the increase in debtors should be monitored.

Registered in England/Wales under the registration number 05464465, with a registered address at E1 8AN, England, London, 63 Mansell Street.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.